Document is current
Any future updates will be listed below
-
Authors
Leta, Gemechu Tadesse https://orcid.org/0000-0001-7623-5381
Mekete, Kalkidan
Wuletaw, Yonas
Gebretsadik, Abeba
Sime, Heven
Mekasha, Sindew
Woyessa, Adugna
Shafi, Oumer
Vercruysse, Jozef
Grimes, Jack E. T.
Gardiner, Iain
French, Michael
Levecke, Bruno
Drake, Lesley
Harrison, Wendy
Fenwick, Alan
-
Funding
Funding for this research was provided by:
Schistosomiasis Control Initiative and Partnership for child development (P43436)
- License Information
-
More Information
Article History
Received: 10 January 2020
Accepted: 25 August 2020
First Online: 1 September 2020
Ethics approval and consent to participate
: The study protocol was approved by the Ethiopian Public Health Institute Scientific and Ethical Review Office (reference number SERO-128-4-2005) and the Institutional Review Board of Imperial College London (reference number ICREC_8_2_2). Official letters were written by the Ethiopian Public Health Institute (EPHI) to the Regional Health and Education Bureaus to obtain regional consent. The school head provided written consent on behalf of the students’ families or guardians as the survey falls under the mandate of the Ministry of Health. Students provided verbal assent to be included in the survey. All students included in the survey were provided with a single oral dose of 500 mg mebendazole (Janssen Pharmaceutical NV, Beerse, Belgium). In addition, students who tested positive for schistosomiasis were provided with 40 mg kg/body weight (measured by a dose-pole) of praziquantel (MerckKGaA, Darmstadt, Germany) [, ].
: Not applicable.
: The authors declare that they have no competing interests.
